Research
'Grand Slam' Pancreatic Cancer Drug Shows Promise as First-Line Treatment
The Brief
- The first-in-class RAS inhibitor daraxonrasib (Rasonque), combined with chemotherapy, showed promise as a first-line treatment for metastatic pancreatic adenocarcinoma (PDAC).
- The reported results come from an early-stage study.
- Source coverage is a short excerpt, so trial size, endpoints and safety data are not available here.
Why it matters
If later trials confirm these early results, a RAS inhibitor combined with chemotherapy could become a new first-line option for metastatic pancreatic cancer, a disease with limited treatment choices.
Who’s affected
- oncologists and pancreatic cancer researchers
- patients with metastatic pancreatic adenocarcinoma
- #pancreatic cancer
- #oncology
- #ras inhibitor
- #clinical trial
- #daraxonrasib
(MedPage Today) -- The first-in-class RAS inhibitor daraxonrasib (Rasonque) in combination with chemotherapy showed promise as a first-line treatment for patients with metastatic pancreatic adenocarcinoma (PDAC), according to results from an early...